HilleVax, Inc., a clinical-stage biopharmaceutical company, develops and commercializes vaccines in the United States. The company develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. It has a license agreement with Takeda Vaccines, Inc. to develop and commercialize HIL-214 pharmaceutical products. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts. Show more

Location: 321 Harrison Avenue, Boston, MA, 02118, United States | Website: https://www.hillevax.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

106.7M

52 Wk Range

$1.34 - $2.17

Previous Close

$2.13

Open

$2.13

Volume

105,528

Day Range

$2.08 - $2.16

Enterprise Value

-36.78M

Cash

159.5M

Avg Qtr Burn

-22.13M

Insider Ownership

17.09%

Institutional Own.

70.85%

Qtr Updated

03/31/25

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
HIL-216 Details Norovirus	Phase 1 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
HIL-214 Details Norovirus	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.